Summary
Large Degree of
Innovation in Parkinson's Disease Pipeline
The Parkinson's disease
(PD) pipeline currently has 302 products in active development across all
stages, but a stark contrast between the mechanisms of action employed in the
current market and the pipeline is evident. Where the market relies on symptomatic
treatments that target neuromodulatory receptors, the pipeline shows a diverse
range of neuroprotective therapies targeting dysfunctional disease processes.
This diversity is partially due to the presence of 90 first-in-class products,
which accounts for 37% of the overall pipeline therapies that disclosed their
target. In an industry, market and development landscape that favors
first-in-class over non-first-in-class development in many ways, such as
through faster approval or greater revenue, this finding has strategic
implications for a wide array of market participants, both large and small.
Despite their historically high attrition rate, first-in-class therapies that
reach the market have the potential to transform and improve the PD treatment
landscape.
Complete report is
available at: http://www.radiantinsights.com/research/frontier-pharma-parkinson-s-disease-identifying-and-commercializing-first-in-class-innovation
Alignment of
First-in-Class Molecular Target with Disease Processes and Genetics
PD is a complex and
multifaceted disease with a complex interplay between different pathological
processes. Enormous research efforts and significant technological advances
have furthered knowledge of the neuroanatomy of the basal ganglia and of the
fundamental processes underlying neurodegeneration, helped by the ongoing
identification of susceptibility genes and causative genes in familial PD.
Although the exact mechanisms that initiate onset remain unclear, these
insights have been translated into the pool of novel therapeutic targets, which
may potentially become disease-modifying therapies by aligning to the disease
processes and some genetic determinants of PD.
GBI Research's
proprietary analysis showed substantial variation in how well the functional
roles of PD first-in-class targets align to the pathophysiology of PD. Further
in-depth analysis identified the most promising first-in-class targets based on
various scientific and clinical parameters. Examining scientific and clinical
data of promising first-in-class targets showed that first-in-class status is
not, in its own right, enough for a successful product; however, the
first-in-class products substantiated by scientific and clinical evidence will
be exciting future prospects with the potential to transform the PD market.
About Radiant Insights
Radiant Insights is a platform for companies looking to meet
their market research and business intelligence requirements. We assist and
facilitate organizations and individuals procure market research reports,
helping them in the decision making process. We have a comprehensive collection
of reports, covering over 40 key industries and a host of micro markets. In
addition to over extensive database of reports, our experienced research
coordinators also offer a host of ancillary services such as, research
partnerships/ tie-ups and customized research solutions.
For More Information Visit – Radiant Insights
Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com
No comments:
Post a Comment